CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

/C O R R E C T I O N -- Octapharma/

Data Readoutfibryga®Neutral
AI Analysis

Summary

Octapharma issued a correction to a previously released news statement regarding a secondary analysis of the FIBRES trial subgroups comparing fibryga® to cryoprecipitate in blood component transfusions.

Clinical Trial Data

Importance:2/10
Sentiment:
0.00
CorrectionData AnalysisfibrygaFIBRES StudyBlood Components

Read the original article

Published by PR Newswire Pharma on September 11, 2026 3:36 PM

Read Original